Navigation Links
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Date:9/14/2009

R compared to TAXUS (4.1 percent for XIENCE V vs. 6.8 percent for TAXUS, p-value=0.03)**, and a 41 percent reduction in the risk of cardiac death or heart attack (MI) compared to TAXUS (3.8 percent for XIENCE V vs. 6.3 percent for TAXUS, p-value=0.04)**.

In March 2009 at the American College of Cardiology annual meeting, Abbott presented long-term data from the SPIRIT II clinical trial of 300 patients, which showed that patients treated with XIENCE V continue to experience fewer heart attacks, deaths or repeat procedures at the target lesion compared to patients treated with TAXUS out to three years. XIENCE V demonstrated a 57 percent reduction in the risk of MACE compared to TAXUS at three years (6.4 percent for XIENCE V vs. 14.9 percent for TAXUS, p-value=0.029)**.

In addition, there was no occurrence of stent thrombosis between two and three years with XIENCE V, and a low rate of stent thrombosis from zero to three years, per Academic Research Consortium (ARC) definition of definite/probable stent thrombosis (0.9 percent for XIENCE V and 2.8 percent for TAXUS, p-value=0.27)** in the SPIRIT II trial. The ARC definitions of stent thrombosis were developed to eliminate variability in the definitions across various drug eluting stent trials.

In May 2009 at EuroPCR, Abbott presented one-year data from the SPIRIT V (five) international, single-arm study, which evaluated XIENCE V in 2,663 patients - including more than 60 patients enrolled at two sites in China. XIENCE V demonstrated low rates of repeat procedure (target lesion revascularization or TLR), stent thrombosis and MACE in a diverse, "real world" population of patients and lesion types, including patients with diabetes, patients with multi-vessel disease and patients with highly complex lesions. In the SPIRIT V study, XIENCE V demonstrated a very low 1.8 percent rate of TLR, a 0.7 percent rate of definite/probable stent thrombosis and a 5.1 percent rate
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
2. Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
3. Abbott HIV Test Demonstrates Earlier Disease Detection
4. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
5. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
6. Abbott Named One of the Top 10 Companies for Scientists
7. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
8. Abbott to Present at Barclays Global Healthcare Conference
9. Abbott Employee Giving Sets New Records for Employee Participation and Total Donations
10. Abbott Announces 11 Percent Increase in Quarterly Dividend
11. Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Rancho BioSciences , the scientific ... curated public data source TCGA for several ... data is now available for other oncology groups. ... internal data sources for their Pharma, Government and academic ... data that becomes more easily accessible. Rancho advises ...
(Date:10/30/2014)... Spartan Bioscience announced today that Health ... . It detects CYP2C19 genetic mutations in less than ... Spartan RX CYP2C19 System is the first near-patient DNA ... Canada. Due to the system’s ease of use, Health ... healthcare professionals such as doctors, nurses, pharmacists, and laboratory ...
(Date:10/30/2014)... 2014 Avure Technologies celebrates a year of ... member of its fleet of high volume High Pressure Processing ... as we return to PackExpo this year, which is where ... Vegas,” said Jeff Williams, CEO at Avure. “Sales of the ... to be meeting the challenges of market demand for higher ...
(Date:10/30/2014)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a company overview at the Nomura Biotechnology Conference on Thursday, ... Boston, MA. A live webcast of ... section of the Company,s website, www.isispharm.com .  A replay ... and will be archived for a limited time. ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... 3.0 ,First the Boom, Then the Bust, Now ... York Times Award-winning Journalist to Address Madison Business, ... Times to Discuss Dotcom and Technology Future. , ... in the Monday Business section of The New ...
... Its Saturday night. Your 4 year old has stomach pains, ... provide all sorts of personal medical information including her medical history ... pain, and you try to remember if you told the person ... or two as the triage nurse does not see bleeding or ...
... promoted Wendel Barr to the position of president, early ... position of president, early development, in Harrogate, UK. ... decision-making employed by its clients in the preclinical segment. ... senior vice presidents and also wil serve on the ...
Cached Biology Technology:Childrens Medical Hospital of Wisconsin Goes Digital 2Childrens Medical Hospital of Wisconsin Goes Digital 3Childrens Medical Hospital of Wisconsin Goes Digital 4Covance Appoints Co-Presidents for Early Development Services 2
(Date:10/29/2014)... kind of stem cell, those referred to as ,facultative, ... is apparently nothing that differentiates these cells from the ... they retain the capacity to become stem cells again. ... an organ that hosts cells that stimulate tissue growth, ... case of a transplant. Knowledge of the underlying ...
(Date:10/29/2014)... — Cambridge, MA and Hebei, China — BGI Tech ... quality sequencing of the Jujube genome. Jujube is the ... the Jujube genome is particularly difficult to sequence due ... It is the first time that a genome in ... has been recently published in Nature Communications ...
(Date:10/29/2014)... 2014 – Ghrelin is a hormone released by the ... is commonly viewed as a psychoactive substance that primarily ... caloric food. , This knowledge, combined with findings ... ghrelin has the potential to stimulate alcohol craving. , ... humans and found that, as they had anticipated, alcohol ...
Breaking Biology News(10 mins):A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Ghrelin stimulates an appetite for drinking alcohol 2
... that increases your risk for Alzheimer,s disease? And what if you ... you,re old but when you,re young? Brace yourself. ... to the development of late-onset Alzheimer,s. In 1993, researchers discovered a ... us that triples the risk for getting Alzheimer,s. In 2009, ...
... 3, 2011) Cancer studies from Mercer University (Ga.) ... American Association of Pharmaceutical Scientists, (AAPS) National Biotechnology Conference ... May 18 at the Hilton San Francisco Union Square. ... Cervical Cancer Cervical cancer is the second ...
... evolutionary legacies to become much better at using ... that can power vehicles in the near future, an ... has found. A U.S. Department of Energy (DOE) ... to compare the efficiency of plants and photovoltaic solar ...
Cached Biology News:Alzheimer's risk gene disrupts brain's wiring 50 years before disease hits 2Alzheimer's risk gene disrupts brain's wiring 50 years before disease hits 3AAPS national biotechnology conference to highlight breakthrough cancer treatments 2NREL's multi-junction solar cells teach scientists how to turn plants into powerhouses 2NREL's multi-junction solar cells teach scientists how to turn plants into powerhouses 3
... PS10 ProteinChip Arrays are preactivated with ... free primary amine groups. The PS10 array ... former PS1 array, but with an updated ... spot chips with 2 mm diameter spots ...
... Activator of Caspase/DIABLO Liquid. In 100 ... FREEZE/THAW CYCLES. Amino acid residues 56 - 239 ... ® sequence was expressed in and purified ... along with cytochrome c during apoptosis ...
...
... Fixed clamp trays and universal trays ... Magnetic drive Shaking speed: ... 25 mm amplitude Clamps ... 2000 ml, including Fernbach flasks ...
Biology Products: